ArticleJournal of neuroinflammation2023

Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis.

Carla Rodriguez-Mogeda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.